

Prevalence of Helicobacter Pylori in Long-Term Dialysis Patients

Mojgan Jalalzadeh^{1*}, Fatemeh Mirzamohamadi², Paria Zargham¹

Departments of ¹Nephrology, ²Student Research Center, Zanjan University of Medical Sciences, Zanjan, I.R. Iran

Abstract

Background and Aims: Helicobacter pylori (H. pylori) has been reported to play an important role in the development of gastritis and gastric ulcer. Here we report the prevalence of H. pylori infection in 87 hemodialysis (HD) patients.

Methods: In the present study we investigated the prevalence of H. pylori infection in 87 HD patients by three methods: serum anti-H. pylori IgG, H. pylori stool antigen (HpSAg) and Urease Breath Test (UBT). All the three methods confirmed each other and when 2 out of the 3 methods showed positive findings, patients were regarded as H. pylori -positive. We also assessed the relationship between clinical factors, serum urea nitrogen, creatinine levels, and duration of dialysis, age and gender with the prevalence H. pylori in these patients.

Results: Eighty seven HD patients (48 male and 39 female) with the mean age of 54.4±16.7 years old and mean dialysis duration of 36.2±33.5 months were assessed. Fifty five (63.2%) of them had dyspepsia. The prevalence of H. pylori infection was 44.8%. Multivariate logistic regression analysis revealed the serum urea nitrogen level was significantly associated with H. pylori prevalence (P=0.03, 95% CI: 1.4-35.8). High serum urea nitrogen seems to correlate with a high prevalence of H. pylori infection. The prevalence of H. pylori infection was low in young patients, but high in elderly patients (P=0.04, 95%CI: 0.97-10.3). There was no significant correlation between gender, duration of dialysis, serum Cholesterol, Triglyceride, creatinine, Hemoglobin, albumin, calcium and phosphor and H. pylori infection in these patients.

Conclusions: Among dialysis patients, the proportion of H. pylori-positive patients was not low. Dialysis treatment may influence H. pylori infection.

Keywords: Hemodialysis, End-Stage Renal Disease, Helicobacter Pylori, Prevalence.

Introduction

Patients with chronic renal failure (CRF) present with various clinical symptoms, including nausea, dyspepsia, loss of appetite, epigastric discomfort, and heartburn, as well as histological, physiological, and functional disorders of the gastrointestinal system (1, 2). These symptoms not only decrease the quality of life, but also may affect their nutrition status, thus contributing to the development of malnutrition, which is a potent predictor of morbidity

and mortality in patients with CRF. About 25–75% of patients with CRF undergoing dialysis suffer from a number of gastrointestinal lesions and complications such as: gastric erosions, Peptic ulcer disease, angiodysplasia, and gastrointestinal bleeding (3-10).

**Correspondence:*

Mojgan Jalalzadeh MD

Nephrology & Dialysis Department Valiasr Hosp. Zanjan, I.R Iran.

Tel: 02417270801; Cell: 0912-224-8306

Email: j_mojgan@yahoo.com

Received: 18 Apr 2010

Revised: 5 May 2010

Accepted: 17 May 2010

Dialysis patients may have a higher risk of gastric mucosal damages compared with individuals with normal renal function (11, 12) by hypergastrinemia (13) high ammonia levels (14) and enhanced inflammation. It is generally known that *Helicobacter pylori* (*H. pylori*) plays an important role in the pathogenesis of gastritis or gastric ulcer (15). *H. pylori* has high urease activity, and produces ammonia in the presence of urea. In patients with end-stage renal disease (ESRD), blood urea levels are high, and gastric juice urea nitrogen levels are also high (16). *H. pylori* infection promotes the production of a high level of ammonia (17). Ammonia is considered to be an etiological factor involved in gastric mucosal disorders (18). Then, gastrointestinal symptoms in dialysis patients might be caused not only by *H. pylori* infection, but also by high urea levels, decline of gastrointestinal motility, and amyloid protein deposition. Several studies have investigated *H. pylori*; however, many aspects remain to be clarified with regard to *H. pylori* infection in patients with ESRD, especially in patients receiving long-term dialysis. In dialyzed patients, the incidence of ulcer is similar to that in patients who do not receive dialysis (5, 6). Also has been reported that the prevalence of *H. pylori* infection is lower in dialyzed patients (19-20).

In this study, we investigated the relationship between the incidence of *H. pylori* infection by measuring *H. pylori* antibody levels and *H. pylori* stool antigen (HpSAg) and Urease Breath Test (UBT) in patients with ESRD who had dyspepsia.

Materials and Methods

The present study included 87 patients with end-stage of renal disease (ESRD) who had been dialyzed in two HD centers (Valiasr & Beheshti hospitals) in Zanjan, one of provinces of Iran, between 2008 and 2009. Out of eighty-seven ESRD patients, 55 patients had dyspepsia (27 females and 28 males, mean age: 54.4±16.7 years). And among 87 ESRD

patients, 39 patients (44.8%) were proved to be infected with *H. pylori* (21 male and 18 female; mean age 59±16.2 years) and 48 patients (55.2%) were uninfected (27 male, 21 female; mean age 51±17.3 years). To confirm *H. pylori* infection three types of tests were used: Anti *H. pylori* serology, *H. pylori* stool Ag (HpSAg) and urease breath test (UBT). If two tests out of these three tests came out positive, the patients were considered infected.

Exclusion criteria included a history of previous treatment for *H. pylori*, use of any of the proposed antibiotics in the previous six months as well as non-cooperation for doing UBT. All of the patients gave informed consent before their initial evaluation for upper GI tract symptoms. Standard dialysis was performed for 4 hours, three times a week. The mean duration of dialysis was 36.2± 35.6 months (range: 1-192 months).

A blood extraction was performed during the dialysis and patients were asked to take a stool sample for the study. Both serum and feces were immediately frozen at -70°C until analysis.

Sera were tested for *H. pylori* antibodies by a commercial ELISA test in accordance with the manufacturer's instructions. Patients with an antibody titer of 1.8 or more were regarded as positive for *H. pylori*.

An enzyme-linked immunosorbent assay (ELISA) using polyclonal antibodies Premier Platinum HpSAg was also performed in accordance with the manufacturer's specifications.

UBT was also performed using the modified European protocol.

Statistics

For statistical analysis SPSS software version 17 was used. The Chi-square test and the student's t-test were used where appropriate. Parametric data are presented as mean±s.d. and nonparametric data as median (25–75% quartiles). All P-values were two sided, and P-values <0.05 were considered statistically significant.

Results

Eighty seven HD patients, including 48 male and 39 female with mean age of 54.6 ± 16.7 years on dialysis for 36.2 months were selected. Thirty nine patients were diagnosed with *H. pylori* infection (21 male and 18 female; mean age 59 ± 16.2 years range) and 48 (27 male, 21 female; mean age 51 ± 17.3 years, range) were found uninfected according to the serology, stool antigen test or 13 C-urea breath test.

With respect to age, 34.2 % of HD patients were less than 50 years old had *H. pylori*. The percentage in the patients at the range of 50 to 79 years was 50% and, 75 percent of the patients older than 80 years of age were positive for *H. pylori*.

The prevalence of *H. pylori* infection was low in young patients, but high in elderly patients ($P = 0.04$, 95%CI: 0.97-4.3).

With respect to serum urea nitrogen, results indicate that high serum urea nitrogen seems to correlate with a high prevalence of *H. pylori* infection. Multivariate logistic regression analysis revealed that the serum urea nitrogen level was significantly associated with *H. pylori* prevalence ($P = 0.03$, 95%CI: 1.4-35.8).

There was no significant correlation between gender, duration of dialysis, serum cholesterol, triglyceride, creatinine, hemoglobin, albumin, calcium and phosphorus and *H. pylori* infection in these patients (Table 1).

Discussion

Helicobacter pylori is considered to be the cause of gastritis and gastric ulcer. It is also closely associated with some other gastrointestinal diseases, such as gastric hyperplastic polyps, gastric adenoma, gastric cancer, and gastric mucosa-associated lymphoid tissue lymphoma (21-23).

With regard to *H. pylori* infection in patients with ESRD, many issues remain to be clarified. We investigated the prevalence of *H. pylori* infection in our HD patients. The results of our study found out that the prevalence of *H. pylori* infection was not low in these group patients.

H. pylori infection between patients with renal failure and patients without chronic renal failure

In Japan, Tokushima performed biopsies, and reported that there was no significant difference in the proportion of *H. pylori* –positive patients between

Table 1. Demographic and laboratory parameters between *H. pylori* positive and negative HD patients

Variables	<i>H. pylori</i> positive N=39 (44.8%)	<i>H. pylori</i> negative N=48 (55.2%)	P value
Gender (F/M)	18/21	21/27	0.83
Age (years)	59 ± 16.2	51 ± 17.3	0.04
Duration of dialysis (months)	43.1 ± 35.4	30.6 ± 28.9	0.1
Dyspepsia	25	30	0.52
Serum albumin	4.1 ± 0.5	4.2 ± 0.6	0.5
Triglyceride	158 ± 76	166 ± 83	0.7
Cholesterol	175 ± 102	179 ± 98	0.6
BUN	94 ± 47	75 ± 32	0.03
Creatinine	10 ± 2.9	9.9 ± 3.5	0.9
Hemoglobin	10.4 ± 2.1	10.3 ± 1.9	0.8
Calcium	9.5 ± 1	9.5 ± 1.1	0.8
KT/V	1.15 ± 0.3	1.29 ± 0.2	0.1

patients with renal failure and patients without chronic renal failure (24). Recently, associations between patients with CRF and the prevalence of *H. pylori* infection have been reported (17, 19, 25-27).

Association H. pylori with progression of renal dysfunction

Although there is no significant evidence that *H. pylori* infection is directly associated with progression of renal dysfunction, patients receiving chronic HD and continuous ambulatory peritoneal dialysis (CAPD) often incur gastrointestinal troubles over their long treatment period (3-9).

Dialysis patients frequently develop gastric/duodenal ulcers (8). If *H. pylori* is involved in the development of ulcers in patients with renal failure, as is frequently reported, eradication therapy should be aggressively performed (22, 28). However, few studies have reported *H. pylori* infection in long-term dialysis patients. The relationship between *H. pylori* and ulcers in patients with renal failure is unclear.

H. pylori infection between the dialysis patients and healthy adults

Many studies have found no difference in the prevalence of *H. pylori* infection between dialysis patients and healthy adults. The prevalence of *H. pylori* infection was 70% or more in Japanese adults (29). The prevalence has decreased annually to levels similar to those reported in Europe and the United States (30). Patients receiving dialysis had significantly lower prevalence of *H. pylori* infection in five studies (19, 25, 31).

Jaspersen et al (19) reported that 37.0% of adults with normal renal function were positive for *H. pylori*, while 20.6% of patients receiving dialysis were positive for *H. pylori*.

Yildiz et al (3) indicated that the incidences of *H. pylori* infection were 72.5% and 65.9% in normal controls and patients receiving dialysis, respectively.

The prevalence of *H. pylori* infection in patients receiving CAPD, chronic dialysis, or kidney transplant was reported to be equal or lower when compared to the subjects with normal renal function in various populations (4-6).

Sugimoto et al (32) investigated the largest number of dialysis patients with a variety of treatment periods, and found that the prevalence of *H. pylori* infection in dialysis patients was significantly lower than in patients with normal renal function. In this study, there was no significant difference in the prevalence of *H. pylori* infection between patients with normal renal function and patients receiving less than 1 year of dialysis. Therefore, his conclusion was that the urea concentration and the antibiotic usage are unlikely contributors to decrease the prevalence of infection.

Only a few studies have indicated that the prevalence of *H. pylori* infection is higher in dialysis patients (7). Khedmat et al reported a total of 474 subjects (71 CRF, 73 HD, 25 transplanted, and 305 controls), that were evaluated for dyspepsia, excluding those receiving any *H. pylori* eradication therapy. All subjects were examined for esophagus, stomach and duodenum mucosa, and infection with HP on 2 distinct tissue samples of the antral region. *H. pylori* infection was found to be higher in the uremic patients (CRF, 66.2%; HD, 63%) than in the renal transplant recipients (40%) and controls (34.8%); $P < 0.001$.

Fabrizi et al reported *H. pylori* antibody levels in 228 dialysis patients, and reported that 56% of dialysis patients and 53% of non-dialysis patients were positive for *H. pylori* (33). In Japan, Tokushima indicated that the proportion of *H. pylori*-positive patients increased after dialysis was introduced (24).

There are at least three explanations as to why dialysis patients have low prevalence of *H. pylori* infection: 1) blood urea levels as well as urea nitrogen levels in gastric secretions are higher in dialysis patients than in patients with normal renal function, and high urea levels inhibit *H. pylori* growth in the stomach (34); 2) *H. pylori* might be eradicated upon

antibiotic treatment, both because antibiotics are commonly used during the initial treatment periods, and because antibiotic concentrations are higher in patients with renal failure; 3) Patients receiving dialysis have higher levels of pro-inflammatory cytokines, including interleukins-1b, 6 and 8, and tumor necrosis factor, from activated inflammatory cells infiltrating the gastric mucosa (35). As a result, the gastric atrophy progresses, accompanied by increased pH, and finally *H. pylori* are not able to live in gastric mucosa (36).

High serum urea nitrogen correlates with prevalence of *Helicobacter pylori* infection

Some investigators focused on the higher concentration of urea in the gastric juice of renal failure patients raising the local gastric pH and providing abundant substrate for *H. pylori* (7, 34). On the other hand, other investigators concluded that the higher levels of urea in the mucus of stomach in renal failure patients may result in a lower prevalence of *H. pylori* colonization in these patients (32). Results of the study Tsukada et al indicate that high serum urea nitrogen seems to correlate with a low prevalence of *H. pylori* infection. And hemodialysis patients with high serum urea nitrogen may be protected against *H. pylori* infection 1% and 81 HD (-) patients (69%) (40).

Gladziwa and Loffeld et al (19) reported that the higher urea levels in the blood and gastric juice of patients with renal failure do not seem to be a risk factor for infection with *H. pylori* (34).

Relationship of *H. pylori* with age

Age is a factor closely related to the proportion of *H. pylori*-positive patients. Fumitaka et al. showed that among dialysis patients, the prevalence of *H. pylori* infection was low in all the age groups over 50 years old (41). However, another study in patients on dialysis and without dialysis, it found that there was no relation between age and the incidence of *H. pylori* infection (25).

In this study, we investigated the prevalence of *H. pylori* infection in our HD patients. The main drawback of this study was the sample size which is small. The results of the present study found that the prevalence of *H. pylori* infection was not low in HD patients, similar to the results of other Iranian population study, which has been done by Khedmat (7).

We indicated that high serum urea nitrogen seems to correlate with a high prevalence of *Helicobacter pylori* infection. The prevalence of *H. pylori* infection was lower in young patients compared with the elderly patients. There was no significant correlation between gender, duration of dialysis, serum cholesterol, triglyceride, creatinine, hemoglobin, albumin, calcium and phosphorus and *H. pylori* infection in these patients.

We conclude that in order to extend the results of this study to Iranian population; studies with larger sample size are required.

Acknowledgements

This work was supported by grants from Iran's Zanjan University of Medical Sciences.

Conflict of Interest

None declared.

References

1. Var C, Gultekin F, Candan F, et al. The effects of hemodialysis on duodenal and gastric mucosal changes in uremic patients. *Clin Nephrol.* 1996;45:310-4.
2. Kang JY, Ho KY, Yeoh KG, et al. Peptic ulcer and gastritis in uraemia, with particular reference to the effect of *Helicobacter pylori* infection. *J Gastroenterol Hepatol.* 1999;14:771-8.
3. Yildiz A, Besisik F, Akkaya V, et al. *Helicobacter pylori* antibodies in hemodialysis patients and renal transplant

- recipients. *Clin Transplant*. 1999;13:13-6.
4. Sezer S, Ibis A, Ozdemir BH, et al. Association of Helicobacter pylori infection with nutritional status in hemodialysis patients. *Transplant Proc*. 2004;36:47-9.
 5. Sotoudehmanesh R, Ali Asgari A, Ansari R, et al. Endoscopic findings in end-stage renal disease. *Endoscopy*. 2003;35:502-5.
 6. Prakash J, Agrawal BK. Upper gastrointestinal mucosal lesions in chronic renal failure. *Indian J Gastroenterol*. 1991;10:131-2.
 7. Khedmat H, Ahmadzad-Asl M, Amini M, et al. Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. *Transplant Proc*. 2007;39:1003-7.
 8. Milito G, Taccone-Gallucci M, Brancaleone C, et al. The gastrointestinal tract in uremic patients on long-term hemodialysis. *Kidney Int*. 1985;17:S157-60.
 9. Musola R, Franzin G, Mora R, et al. Prevalence of gastroduodenal lesions in uremic patients undergoing dialysis and after renal transplantation. *Gastrointest Endosc*. 1984;30:343-6.
 10. Wee A, Kang JY, Ho MS, et al. Gastroduodenal mucosa in uraemia: endoscopic and histological correlation and prevalence of helicobacterlike organisms. *Gut*. 1990;31:1093-6.
 11. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney Int*. 2007;71:438-41.
 12. Nakamura S, Sasaki O, Nakahama H, et al. Clinical characteristics and survival in end-stage renal disease patients with arteriosclerosis obliterans. *Am J Nephrol*. 2002;22:422-8.
 13. Gur G, Boyacioglu S, Gul C, et al. Impact of Helicobacter pylori infection on serum gastrin in haemodialysis patients. *Nephrol Dial Transplant*. 1999;14:2688-91.
 14. Leiber CS, Lefevre A. Ammonia as a source of gastric hypoacidity in patients with uremia. *J Clin Invest*. 1959;38:1271-7.
 15. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: A randomized, controlled study. *Ann Intern Med*. 1992;116:705-8.
 16. Paimela H, Stenman S, Kekki M, Sipponen P, Tallgren LG, Scheinin TM. Chronic gastritis and gastric acid secretion in uraemic and renal transplant patients. *Hepatogastroenterology*. 1985;32:15-9.
 17. Neithercut WD, Rowe PA, el Nujumi AM, et al. Effect of Helicobacter pylori infection on intragastric urea and ammonium concentrations in patients with chronic renal failure. *J Clin Pathol*. 1993;46:544-7.
 18. Tsujii M, Kawano S, Tsuji S, Fusamoto H, Kamada T, Sato N. Mechanism of gastric mucosal damage induced by ammonia. *Gastroenterology*. 1992;102:1881-8.
 19. Jaspersen D, Fassbinder W, Heinkele P, et al. Significantly lower prevalence of Helicobacter pylori in uremic patients than in patients with normal renal function. *J Gastroenterol*. 1995;30:585-8.
 20. Loffeld RJ, Peltenburg HG, vd Oever H, Stobberingh E. Prevalence of Helicobacter pylori antibodies in patients on chronic intermittent haemodialysis. *Nephron*. 1991;59:250-253.
 21. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med*. 2001;345:784-9.
 22. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. *Gastroenterology*. 1996;110:1244-52.
 23. Wotherspoon AC, Doglioni C, de Boni M, Spencer J, Isaacson PG. Antibiotic treatment for low-grade gastric MALT lymphoma. *Lancet*. 1994;343:1503.
 24. Tokushima H. Role of Helicobacter pylori in gastroduodenal mucosal lesions in patients with end-stage renal disease under dialysis treatment. *Nippon Jinzo Gakkai Shi*. 1995;37:503-10.
 25. Nakajima F, Sakaguchi M, Amemoto K, et al. Helicobacter pylori in patients receiving long term dialysis. *Am J Nephrol*. 2002;22:468-72.
 26. Schoonjans R, Van VB, Vandamme W, et al. Dyspepsia and gastroparesis in chronic renal failure: the role of Helicobacter pylori. *Clin Nephrol*. 2002;57:201-7.
 27. Strid H, Simren M, Stotzer PO, Abrahamsson H, Bjornsson ES. Delay in gastric emptying in patients with chronic

- renal failure. *Scand J Gastroenterol.* 2004;39:516-20.
28. Take S, Mizuno M, Ishiki K, et al. The effect of eradicating *Helicobacter pylori* on the development of gastric cancer in patients with peptic ulcer disease. *Am J Gastroenterol.* 2005;100:1037-42.
 29. Asaka M, Kimura T, Kudo M, et al. Relationship of *Helicobacter pylori* to serum pepsinogens in an asymptomatic Japanese population. *Gastroenterology.* 1992;102:760-6.
 30. Har-uma K, Okamoto S, Kawaguchi H, et al. Reduced incidence of *Helicobacter pylori* infection in young Japanese persons between the 1970s and the 1990s. *J Clin Gastroenterol.* 1997;25:583-6.
 31. Misra V, Misra SP, Dwivedi M, et al. Decreased sensitivity of the ultrarapid urease test for diagnosing *Helicobacter pylori* in patients with chronic renal failure. *Pathology.* 1999;31:44-6.
 32. Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of *Helicobacter pylori* infection in long-term hemodialysis patients. *Kidney Int.* 2009;75:96-103.
 33. Fabrizi F, Martin P, Dixit V, et al. Epidemiology of *Helicobacter pylori* in chronic haemodialysis patients using the new RIBA H. pylori SIA. *Nephrol Dial Transplant.* 1999;14:1929-33.
 34. Gladziwa U, Haase G, Handt S, et al. Prevalence of *Helicobacter pylori* in patients with chronic renal failure. *Nephrol Dial Transplant.* 1993;8:301-6.
 35. Hwang IR, Kodama T, Kikuchi S, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in *Helicobacter pylori* infection. *Gastroenterology.* 2002;123:1793-803.
 36. Wesdorp RI, Falcao HA, Banks PB, Martino J, Fischer JE. Gastrin and gastric acid secretion in renal failure. *Am J Surg.* 1981;141:334-8.
 37. Huang JJ, Huang CJ, Ruaan MK, Chen KW, Yen TS, Sheu BS. Diagnostic efficacy of (13) C-urea breath test for *Helicobacter pylori* infection in hemodialysis patients. *Am J Kidney Dis.* 2000;36:124-9.
 38. Ozgur O, Boyacioglu S, Ozdogan M, Gur G, Telatar H, Haberal M. *Helicobacter pylori* infection in haemodialysis patients and renal transplant recipients. *Nephrol Dial Transplant.* 1997;12:289-91.
 39. Munoz de Bustillo E, Sanchez Tomero JA, Sanz JC, et al. Eradication and follow-up of *Helicobacter pylori* infection in hemodialysis patients. *Nephron.* 1998;79:55-60.
 40. Tsukada K, Miyazaki T, Katoh H, et al. *Helicobacter pylori* in hemodialysis patients. *Hepatogastroenterology.* 2003;50:2255-8.
 41. Nakajima F, Sakaguchi M, Oka H, Kawase et al. Prevalence of *Helicobacter pylori* antibodies in long-term dialysis patients. *Nephrology.* 2004;9:73-76.